| [1] | Nan WANG, Rong HU, Shihui BIAN, Wei ZHONG, Pengfei ZHANG, Youwen TAN. Value of alkaline phosphatase level after ursodeoxycholic acid treatment for one month and baseline red blood cell distribution width in predicting the treatment response of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(3): 496-501. doi: 10.12449/JCH240310 |
| [2] | Xinyu CUI, Yanyan LI, Na ZHU, Yingying LIN, Xin LI. Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2024, 40(3): 489-495. doi: 10.12449/JCH240309 |
| [3] | WANG WeiZhao, ZHU QinLing, XIANG XiaoXing, MA Li, GU Da, TONG Cong, WANG TingTing, HE JiaJun, LIU Jun, WANG Lu, CHEN ChaoWu. Expression and significance of OX40/OX40L in peripheral blood of patients with autoimmune hepatitis,primary biliary cholangitis,and their overlap syndrome[J]. Journal of Clinical Hepatology, 2020, 36(12): 2740-2745. doi: 10.3969/j.issn.1001-5256.2020.12.020 |
| [4] | Feng Ying, Zhou GuiQin, Yang Li, Li Bin, Wang XianBo. Autoimmune hepatitis-associated liver cirrhosis with primary immune thrombocytopenia: A case report[J]. Journal of Clinical Hepatology, 2020, 36(4): 879-880. doi: 10.3969/j.issn.1001-5256.2020.04.035 |
| [5] | Zhang YuGuo, Zhao SuXian, Li WenCong, Ren WeiGuang, Nan YueMin. Clinical effect of ursodeoxycholic acid combined with diammonium glycyrrhizinate in treatment of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1322-1325. doi: 10.3969/j.issn.1001-5256.2019.06.028 |
| [6] | Xiong KeGong, Ke KunYu, Kong JinFeng, Liu LiJuan, Chen LiFang, Lin XiaoQin. Expression of programmed death-ligand 1 on peripheral blood T cells and its correlation with liver inflammation grade in patients with type 1 autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(6): 1248-1252. doi: 10.3969/j.issn.1001-5256.2018.06.023 |
| [7] | Zhong QiHua, Zhou GuiQin, Wang XianBo, Wang XiaoJing, Wang RongBing, Sun FengXia. Research advances in non-hormonal therapies for autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2016, 32(2): 378-381. doi: 10.3969/j.issn.1001-5256.2016.02.040 |
| [9] | Li YanLi, Zhao Yan, Yan HuiPing. Evolution of regulatory T cells in pathogenesis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(5): 332-334. |
| [10] | Hu XingWu, Qi ChangJin, Zhou HongXing. Therapeutic efficacy of ursodeoxycholic acid for drug-induced liver disease[J]. Journal of Clinical Hepatology, 2012, 28(9): 695-696. |
| [11] | Zhao Qing, Xin ShaoJie, Hou Jun, Hu Yan, Mao PanYong. Detection high mobility group box-1 protein in autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2009, 25(2): 118-119. |
| [12] | Zhao Yan, Yan HuiPing, Tan YuFen, Liu Yan, Ma DongMei, Feng Xia, Li WeiHua. Clinical and laboratory characters of the liver dysfunctional patients with antibodies to double-stranded DNA.[J]. Journal of Clinical Hepatology, 2008, 24(1): 10-12. |
| [13] | Gao Feng, Zhang FuKui, Jia JiDong. Liver function changes of ursodeoxycholic acid made in china for patients with primary biliary cirrhosis.[J]. Journal of Clinical Hepatology, 2008, 24(4): 278-280. |
| [14] | Qin Gang, Shi GuangFeng, Li Qian, Lu Qing, Chen Shu. Inhibitory effects of UDCA on porcine serum-induced rat liver fibrosis[J]. Journal of Clinical Hepatology, 2007, 23(4): 263-265. |
| [17] | Wang JingQuan, Cui ShiChang, Yan HuiPing, Dong ShengShan, Li DongCeng, Zhu RenPing. The clinical observation of autoantibody in autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2004, 20(1): 12-13. |
| [18] | Zhang ShiBin, Yan HuiPing, Tao MingLing, He LiXiang, Wang JunTao. Clinical Study of the Diagnostic Scoring System of Autoimmune Hepatitis[J]. Journal of Clinical Hepatology, 2002, 18(6): 330-332. |
| [19] | Zhao Hong, Si ChongWen, Wang QinHuan. Diagnosis of Autoimmune Hepatitis: Case Report and Review[J]. Journal of Clinical Hepatology, 2001, 17(2): 97-98. |
DownLoad: